0001493152-22-007952.txt : 20220329 0001493152-22-007952.hdr.sgml : 20220329 20220329080034 ACCESSION NUMBER: 0001493152-22-007952 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220329 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220329 DATE AS OF CHANGE: 20220329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novo Integrated Sciences, Inc. CENTRAL INDEX KEY: 0001138978 STANDARD INDUSTRIAL CLASSIFICATION: ENGINES & TURBINES [3510] IRS NUMBER: 593691650 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40089 FILM NUMBER: 22777456 BUSINESS ADDRESS: STREET 1: 11120 NE 2ND STREET STREET 2: SUITE 100 CITY: BELLEVUE STATE: WA ZIP: 98004 BUSINESS PHONE: (206) 617-9797 MAIL ADDRESS: STREET 1: 11120 NE 2ND STREET STREET 2: SUITE 100 CITY: BELLEVUE STATE: WA ZIP: 98004 FORMER COMPANY: FORMER CONFORMED NAME: TURBINE TRUCK ENGINES INC DATE OF NAME CHANGE: 20010420 8-K 1 form8-k.htm
0001138978 false 0001138978 2022-03-29 2022-03-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest reported): March 29, 2022

 

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40089   59-3691650
(State or other jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification Number)

 

11120 NE 2nd Street, Suite 100, Bellevue, WA 98004

(Address of principal executive offices)

 

(206) 617-9797

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on which Registered
Common Stock, $0.001 par value   NVOS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

On March 29, 2022, Novo Integrated Sciences, Inc. (the “Company”) issued a press release announcing execution of a memorandum of understanding with Boditech Med, a global point-of-care testing leader (“Boditech”), for a marketing and distribution partnership for the launch and deployment of Boditech’s in-vitro diagnostic solutions and technology in North America.

 

The information included in Item 7.01 to this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
99.1   Press release issued by the registrant on March 29, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Novo Integrated Sciences, Inc.
     
Dated: March 29, 2022 By: /s/ Robert Mattacchione
    Robert Mattacchione
    Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Novo Integrated Sciences Signs Memorandum of Understanding with Boditech Med, a Global Point-of-Care Testing Leader, to Market and Distribute in North America

 

BELLEVUE, Wash., March 29, 2022 - Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the signing of a memorandum of understanding with Boditech Med, a global point-of-care testing leader (“Boditech”), for a marketing and distribution partnership for the launch and deployment of Boditech Med’s in-vitro diagnostic solutions and technology in North America.

 

Founded in South Korea in 1998, Boditech markets and sells more than 90 biomarker products in 120 countries. Boditech offers highly reliable in-vitro diagnostic solutions that empower clinicians and patients to improve health through quick and reliable tests, available anywhere and anytime. Along with venous blood and plasma testing, Boditech’s product line includes technologies that enable accurate, thorough capillary blood tests, based on a small amount of blood from a finger prick. Boditech also produces COVID-19 antibody and over-the-counter rapid antigen tests.

 

Boditech recently announced plans to open a manufacturing site in Miami, Florida and is currently seeking approvals from the U.S. Food and Drug Administration for several diagnostic solutions in cardiac, cancer, hormone, infectious disease, and other therapeutic areas. Boditech intends to bring lower-cost, rapid testing that covers many critical areas of medicine, from cardiac health to cancer, to North America.

 

Robert Mattacchione, Novo’s CEO and Board Chairman, commented, “On March 23, 2022, Novo announced it had entered into a purchase agreement to acquire Clinical Consultants International LLC (“CCI”), a global consulting firm specializing in providing value-added services for multiple sectors of the medical industry. One of the many benefits CCI offers Novo is CCI’s portfolio of leading multi-national healthcare clients, assisting each through clinical and regulatory development as well as entrance into new markets. Boditech is one such CCI client. I want to thank both Dr. Joseph Chalil, for his many years of leadership of CCI and for introducing Boditech to Novo, along with Eui-Yul Choi, Boditech’s co-founder and CEO, for selecting Novo to provide Boditech with the ecosystem and the platform to quickly and efficiently market and distribute Boditech’s in-vitro diagnostic solutions in North America. With Boditech’s planned expansion into North America, together we will improve the health and safety of patients and the effectiveness and workflow of clinicians.”

 

Dr. Choi stated, “Diagnostic testing in North America remains a critical issue for patients, many times taking up to an astounding three days to get test results. Our proven technology is more cost effective with actionable results in as little as 12 to 15 minutes. We recently announced our intention to establish manufacturing capabilities in Miami, Florida and today are pleased to have identified our marketing and distribution partner, Novo Integrated Sciences, for the deployment of our technology in North America.”

 

About Boditech Med

 

Boditech Med is a global leader in point-of-care testing with a decades-long track record of improving health and quality of life through innovative in-vitro diagnostic solutions. Since its launch in 1998, Boditech has developed 85 biomarkers, which support capillary blood, venous blood, and plasma testing, to meet customers’ evolving needs. Listed as a public company on the KOSDAQ, Boditech’s products aid patients and clinicians in 120 countries.

 

 

 

 

Learn more about Boditech Med and how its in-vitro diagnostic are improving health worldwide, please visit https://www.boditech.co.kr/en

 

About Novo Integrated Sciences, Inc.

 

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, diagnostic and therapeutic solutions, and rehabilitative science.

 

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

 

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

 

●First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
   
●Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
   
●Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

 

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.

 

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com . For more information on Novo Healthnet Limited, Novo’s wholly owned subsidiary, please visit www.novohealthnet.com

 

Twitter, LinkedIn, Facebook, Instagram, YouTube

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

 

Contact

 

Novo Integrated Sciences

Chris David, COO-President

chris.david@novointegrated.com

(888) 512-1195

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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

/GBBT0PZ/+_859U?Q7JFDI&[ M: K((%EF+WT:;21EE4'EB.1QZ5<<1.*LI">!JW2:U=^JZ:=^Y?T#P=H7AKYM M-L428C!G<[Y#^)Z?ABMVO/\ 7/&^I;?#MUHMD[VNH2+D,R R'=@Q<_=/'WNG M-:6I^-9+.\ATZWTQ9=1,"S7$,MVD2P9Q\I<\%N>U0Y\SNV5]1K)*RWOU6EG9 MW['75QWBKX;Z/XLU%+^YEN;>X"!&:!E <#ID$'FD;XAVDFCVUS:64T]]8,9!;ICD<^X]\4=(UG5;[XF_9[ZVN+ +IQ+6;3[TW;OOC'!X/6B-1P M=XL/J-7EDYJUDWKY>7SWV.OT+1+/P]H\&F6*L((0<%CEF).22?7-:-<5X[U7 M5-.N=.2&>XL]+D+?:[RWA\QTQT'L/\]L4FE^)++2O#E]JLWB*36;:)EV Q!9 M4)X"D<')/<^E)SN]06#FZ4:D=;[)7[VWV3\F=G+%'/$T4T:21N,,CJ"&'H0: MX;4_A%X6U"5I8HKBR9N2+:3Y?R8''X5<;Q#J=YIU]'JGAN\L;=K.659H[@'Y M0I."P'R,>W4^U4;'Q?;:1X:T6VLK26XN[N)FBAN+I1M4,W>#]R64!3_ -\@']:[JPT^STRT M2UL;:*W@3I'&N!_^NN2D^(D,>@W]\U@1=V$J1SVPG5@-YP&5QD$=?RJSI_C. MXFUVTTW4M$GT\7RE[21Y5?> ,\@?=./Z4Y5I3^)W)^HUHIOEV].FO?71WTZ' M6T5QJ>-[R]EEFTGP[=7^FPRF)KF.50S$=2J'DC_/%.U3QS]FU6XT_3].%W): MJ&N6END@"DC.U=WWC]*CF0_J5:_+;7U6GKKINMSL**XFY^(ML;;3'TZR\^6_ M1G5;B=8$3:2""[<9R#Q]/6NFTV^O+W3XKBXL!;2N#F+SUDQR1]X<'(Y_&A-, MBIAJM-F['F#>#=?BU)+&;39XG8XWNN(P.Y+],>^:]EAT^.STZWM,,L-O""S$8*H[! M 3Z?*I-%%52CRZG3F&/GBE!225M?G_2/,/&'A74O[9EO+6SEG$[@31Q(6:*; M^($#G!.64]""/>M/PQ\)]0OI$N-;S9VN<^2#F5QZ?[/X\^U%%1*FN8W_ +7Q M"H1A&R>U^NA[+8V-KIME%9V<*0P1#"HHX'_U_>K%%%4>2VV[L*X6;X?2RZ!J MVF#44!O[[[6)/*/RS.MTWP?<1/X M7NY[A(Y=)MV22$+NW,RX(!SVS3=8\"RZCKE]J$5];A;V,1NMS:"9HL#&8R3\ MM%%/E1C]=K*7.GKJOO=_S"3P--_PC6CZ?!J0BO=*F\Z&X\K*D[BW*Y]Q^5)J M?@>XO[Z'5%OK4ZD81%S66*;'\05ONGIT]***.5#6-KIWOWZ+KJ_E?6Q+< M>!WFTFP2._C@U2RF,\=W!:I&I8]BB\8X _"I-)\*:C:^*O[>U+6%O9VMC 5$ M C YR,8/3C\R:**.5$O&5G%Q;WOT77=>AIZWIVLWQ2V&K1ZG?&>ZU,JTDL,0C6,J''O\ Q!HFIBY"#3=^8RF?,W #KGCI1119">+JMWOW M_%6?X&7!X,U73'FMM&\0O9Z9+-YOD^0KO&2>0K'MP/\ Z]-U7P&UQK4^IZ?= MVT^Q8O_ E>SV%E:07FG&*" M/;)'/ID;)(YZN /NGZ4[2? \&FZ9#:-J-X[1@Y:-_+4DDGA>W6BBCE1+Q=;E &Y+Z;G__9 end EX-101.SCH 4 nvos-20220329.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 nvos-20220329_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 nvos-20220329_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Mar. 29, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 29, 2022
Entity File Number 001-40089
Entity Registrant Name Novo Integrated Sciences, Inc.
Entity Central Index Key 0001138978
Entity Tax Identification Number 59-3691650
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11120 NE 2nd Street
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Bellevue
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98004
City Area Code (206)
Local Phone Number 617-9797
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol NVOS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001138978 2022-03-29 2022-03-29 iso4217:USD shares iso4217:USD shares 0001138978 false 8-K 2022-03-29 Novo Integrated Sciences, Inc. NV 001-40089 59-3691650 11120 NE 2nd Street Suite 100 Bellevue WA 98004 (206) 617-9797 false false false false Common Stock, $0.001 par value NVOS NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://novointegrated.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm nvos-20220329.xsd nvos-20220329_lab.xml nvos-20220329_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "nvos-20220329_lab.xml" ] }, "presentationLink": { "local": [ "nvos-20220329_pre.xml" ] }, "schema": { "local": [ "nvos-20220329.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NVOS", "nsuri": "http://novointegrated.com/20220329", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-29to2022-03-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://novointegrated.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-03-29to2022-03-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://novointegrated.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-007952-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-007952-xbrl.zip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end